Combined neuroendocrine differentiation and androgen receptor hyperactivity in MAP37 and CHD1 null prostate cancer

被引：0
|
作者：
Rider, Leah C.
Rodrigues, Lindsey U.
Karimpour-Fard, Anis
Romero, Lina
Gillette, Claire
Costello, James C.
Cramer, Scott D.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-1580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1580
引用
收藏
页数：2
相关论文
共 42 条
  • [31] Prolonged Response to an IGF-1 Receptor Antibody in a Patient with Metastatic Castration Prostate Cancer with Neuroendocrine Differentiation
    Graff, Julie N.
    Thomas, George V.
    Higano, Celestia S.
    Beer, Tomasz M.
    CUREUS, 2015, 7 (12):
  • [32] ONECUT2 as a key mediator of androgen receptor-independent cell growth and neuroendocrine differentiation in castration-resistant prostate cancer
    Choi, WonSeok William
    Boland, Julia L.
    Lin, Jianqing
    CANCER DRUG RESISTANCE, 2022, 5 (01) : 165 - 170
  • [33] Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer
    Revelos, Kyriakos
    Petraki, Constantina
    Scorilas, Andreas
    Stefanakis, Stefanos
    Malovrouvas, Dimitrios
    Alevizopoulos, Nektarios
    Kanellis, George
    Halapas, Antonis
    Koutsilieris, Michael
    ANTICANCER RESEARCH, 2007, 27 (5B) : 3651 - 3660
  • [34] Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals
    Dang, Qiang
    Li, Lei
    Xie, Hongjun
    He, Dalin
    Chen, Jiaqi
    Song, Wenbing
    Chang, Luke S.
    Chang, Hong-Chiang
    Yeh, Shuyuan
    Chang, Chawnshang
    MOLECULAR ONCOLOGY, 2015, 9 (07) : 1241 - 1251
  • [35] 68Ga-DOTA-NT-20.3 Neurotensin Receptor 1 PET Imaging as a Surrogate for Neuroendocrine Differentiation of Prostate Cancer
    Wu, Wenyu
    Yu, Fei
    Zhang, Pengjun
    Bu, Ting
    Fu, Jingjing
    Ai, Shuyue
    You, Qinqin
    Shi, Liang
    Shao, Guoqiang
    Wang, Feng
    Hodolic, Marina
    Guo, Hongqian
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (09) : 1394 - 1400
  • [36] Phase 1b study of bavdegalutamide, an androgen receptor PROTAC degrader, combined with abiraterone in patients with metastatic prostate cancer
    Shore, Neal D.
    Shen, John
    Devitt, Michael Edward
    Lu, Haolan
    Alicea, Jeanette
    Parameswaran, Janaki
    Chirnomas, Deborah
    Gao, Xin
    McKean, Meredith
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression
    Lee, Soo Ok
    Chun, Jae Yeon
    Nadiminty, Nagalakshmi
    Lou, Wei
    Gao, Allen C.
    PROSTATE, 2007, 67 (07): : 764 - 773
  • [38] The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells
    Hong, Seung-Keun
    Kim, Jin-Hwan
    Lin, Ming-Fong
    Park, Jong-In
    EXPERIMENTAL CELL RESEARCH, 2011, 317 (18) : 2671 - 2682
  • [39] JARID1D-dependent androgen receptor and JunD signaling activation of osteoclast differentiation inhibits prostate cancer bone metastasis through demethylating H3K4
    Hu, Yaohua
    Zhao, Zhite
    Xie, Qinghua
    Li, Hui
    Zhang, Chenyang
    He, Xinglin
    Ma, Yifan
    Zhang, Caiqin
    Li, Qinlong
    Shi, Changhong
    THERANOSTICS, 2025, 15 (04): : 1320 - 1337
  • [40] RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor
    Narayanan, Bhagavathi A.
    Narayanan, Narayanan K.
    Davis, Leland
    Nargi, Dominick
    MOLECULAR CANCER THERAPEUTICS, 2006, 5 (05) : 1117 - 1125
12345